That’s why adjunctive therapies — sometimes called “add-ons” — are often needed to reduce the incidence of breakthrough symptoms like agitation, fatigue, social withdrawal, impulsivity, and others, explains says Jonathan Terry, DO, a psychiatrist and the assistant dean at California Health Sciences University College of Osteopathic Medicine in Clovis, California.
“While lithium and valproate remain the cornerstone of treatment, clinical experience aligns with the data: A significant majority of patients require a multimodal approach to achieve true functional recovery,” he says.
- Sleep disturbances, such as insomnia, trouble staying asleep, and difficulty adhering to a sleep schedule
- Significant changes in mood, including irritability, elevated mood, and sadness
- Pacing or fidgeting
- Changes in appetite, including both increased and decreased appetite
- Racing thoughts or obsessive interest in new projects
- Loss of interest in usual activities or social connections
Often, an add-on medication can reduce the frequency and duration of breakthrough episodes, and the choice of adjunctive therapy depends on what type of symptoms you’re experiencing most, says Dr. Terry. Here are seven medications to consider.
1. Lamotrigine (Lamictal) for Depression-Heavy Cycles
Lamotrigine (Lamictal) is actually an anticonvulsant medication, but over time has been found to be potentially helpful for stabilizing mood and reducing depression by calming overactive nerves in the body.
“This would not be a first-line medication like lithium or valproate, but can be very helpful for many with bipolar,” explains Douglas Misquitta, MD, a psychiatrist and an assistant clinical professor of psychiatry and behavioral health at the Ohio State University Wexner Medical Center in Columbus, Ohio. “The key is slow increase in the dose, no faster than every two weeks, to reduce the risk of a potentially serious side effect called Stevens-Johnson syndrome, which can affect various organs of the body,” Dr. Misquitta says. “However, this is a rare development.”
2. Cariprazine (Vraylar) for Balanced Control
It came to market in 2023 and is one of the few medications that are approved by the U.S. Food and Drug Administration (FDA) for both manic/mixed episodes and bipolar depression. It may be best for people living with bipolar who need a “top-down” approach for mania and also struggle with depressive dips.
3. Lumateperone (Caplyta) for Bipolar Depression
Lumateperone targets the brain chemicals serotonin, dopamine, and glutamate simultaneously. It may help by targeting the “lows” of bipolar 1 or 2 with a focus on tolerability.
It’s also known for a lower risk of weight gain and movement disorders (extrapyramidal symptoms) compared with older antipsychotics.
4. Aripiprazole (Abilify) for Energy Regulation
Side effects can include weight gain, negative effects on cholesterol and blood sugar (increasing diabetes risk over time), and can in some people cause a very uncomfortable restlessness called akathisia, Misquitta adds.
5. Quetiapine (Seroquel) for Comprehensive Coverage
Quetiapine (Seroquel) is another atypical antipsychotic. At lower doses, it’s highly sedating and aids with the insomnia often seen in bipolar disorder, says Terry. At higher doses, it provides powerful anti-manic and anti-depressive effects.
“The primary benefit is its efficacy across the entire mood spectrum,” he says. “However, considerations must include the risk of metabolic syndrome, requiring regular monitoring of weight, blood glucose, and lipid profiles.”
6. Lurasidone (Latuda) for Stubborn Bipolar Depression
Lurasidone (Latuda) is an atypical antipsychotic used in schizophrenia and bipolar depression. It affects how your brain uses both dopamine and serotonin to provide better mood regulation.
“It is a potent option for bipolar depression,” says Hussain Abdullah, MD, a psychiatrist and an assistant professor of psychiatry at Hackensack Meridian School of Medicine in New Jersey. “A critical practical consideration is that it must be taken with a meal of at least 350 calories to ensure proper absorption; without this, the clinical efficacy is significantly diminished.”
7. Emerging NMDA Modulators (Ketamine) for Rapid Response
Ketamine is not FDA-approved to treat bipolar disorder. But researchers are looking into whether it is safe and effective for this purpose, and some doctors prescribe it off-label. NMDA modulators target the neurotransmitter glutamate rather than serotonin or dopamine.
“Ketamine and other NMDA modulators represent a significant shift toward rapid-acting antidepressant effects by targeting the glutamate system,” Dr. Abdullah says. “This intervention may be appropriate for treatment-resistant bipolar depression where traditional agents have failed, or in acute situations where suicidal ideation requires immediate mitigation.”
These modulators can serve as a “bridge” to provide quick, temporary relief while long-term stabilizers are adjusted and optimized, he adds.
Dr. Peay emphasizes, “The use of agents like ketamine for psychiatric and other medical indications is still investigational. The safety and efficacy have not been fully reviewed by the FDA for bipolar specifically.”
Read the full article here
